Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 19/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958721 | 1.00 | AGTR2 (0.56) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL29958648 | 0.93 | AGTR2 (0.51) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL23831132 | 0.93 | AGTR2 (0.47) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL25576378 | 0.92 | AGTR2 (0.57) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL29958619 | 0.92 | AGTR2 (0.53) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL29958896 | 0.91 | AGTR2 (0.61) | AGTR2AGTR1 | |
| SCHEMBL25576364 | 0.91 | AGTR2 (0.61) | AGTR2AGTR1 | |
| SCHEMBL29958604 | 0.91 | AGTR2 (0.48) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL30672031 | 0.90 | AGTR2 (0.54) | AGTR2CYP3A4AGTR1 | |
| SCHEMBL29958715 | 0.90 | AGTR2 (0.54) | AGTR2CYP3A4AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | AGTR2, AGTR1, AGT | AGTR2 1/4885CYP3A4 4131/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.